Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis

Acta Ophthalmol (Copenh). 1983 Feb;61(1):51-7. doi: 10.1111/j.1755-3768.1983.tb01394.x.

Abstract

Eight patients with active toxoplasmic retinochoroiditis were treated with clindamycin and a triple sulphonamide combination for a period of up to 6 weeks. In addition systemic prednisone was administered when the optic nerve or the macula was involved (6 of the 8 cases). In all cases we observed clinical improvement within 2 weeks. Visual acuity improved in all cases. Side effects of the treatment were observed in 2 cases. The follow-up period ranged from 8 to 22 months.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Clindamycin / therapeutic use*
  • Drug Combinations
  • Drug Therapy, Combination
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Humans
  • Male
  • Prednisone / therapeutic use*
  • Recurrence
  • Sulfadiazine / therapeutic use
  • Sulfamethazine / therapeutic use
  • Sulfanilamides / therapeutic use
  • Sulfonamides / therapeutic use*
  • Toxoplasmosis, Ocular / drug therapy*
  • Visual Acuity

Substances

  • Drug Combinations
  • Sulfanilamides
  • Sulfonamides
  • Sulfadiazine
  • Clindamycin
  • Sulfamethazine
  • Prednisone
  • sulfanilylurea